Show simple item record

Advances in Gene Therapy for Diseases of the Eye

dc.contributor.authorPetit, Lolita
dc.contributor.authorKhanna, Hemant
dc.contributor.authorPunzo, Claudio
dc.date2022-08-11T08:09:20.000
dc.date.accessioned2022-08-23T16:26:56Z
dc.date.available2022-08-23T16:26:56Z
dc.date.issued2016-08-01
dc.date.submitted2017-04-20
dc.identifier.citationHum Gene Ther. 2016 Aug;27(8):563-79. doi: 10.1089/hum.2016.040. Epub 2016 Jun 13. <a href="https://doi.org/10.1089/hum.2016.040">Link to article on publisher's site</a>
dc.identifier.issn1043-0342 (Linking)
dc.identifier.doi10.1089/hum.2016.040
dc.identifier.pmid27178388
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36668
dc.description.abstractOver the last few years, huge progress has been made with regard to the understanding of molecular mechanisms underlying the pathogenesis of neurodegenerative diseases of the eye. Such knowledge has led to the development of gene therapy approaches to treat these devastating disorders. Challenges regarding the efficacy and efficiency of therapeutic gene delivery have driven the development of novel therapeutic approaches, which continue to evolve the field of ocular gene therapy. In this review article, we will discuss the evolution of preclinical and clinical strategies that have improved gene therapy in the eye, showing that treatment of vision loss has a bright future.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27178388&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsCopyright Lolita Petit et al., 2016; Published by Mary Ann Liebert, Inc.
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCellular and Molecular Physiology
dc.subjectEye Diseases
dc.subjectMolecular Biology
dc.subjectTherapeutics
dc.titleAdvances in Gene Therapy for Diseases of the Eye
dc.typeJournal Article
dc.source.journaltitleHuman gene therapy
dc.source.volume27
dc.source.issue8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1035&amp;context=metnet_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/metnet_pubs/36
dc.identifier.contextkey10046371
refterms.dateFOA2022-08-23T16:26:56Z
html.description.abstract<p>Over the last few years, huge progress has been made with regard to the understanding of molecular mechanisms underlying the pathogenesis of neurodegenerative diseases of the eye. Such knowledge has led to the development of gene therapy approaches to treat these devastating disorders. Challenges regarding the efficacy and efficiency of therapeutic gene delivery have driven the development of novel therapeutic approaches, which continue to evolve the field of ocular gene therapy. In this review article, we will discuss the evolution of preclinical and clinical strategies that have improved gene therapy in the eye, showing that treatment of vision loss has a bright future.</p>
dc.identifier.submissionpathmetnet_pubs/36
dc.contributor.departmentUMass Metabolic Network
dc.contributor.departmentGene Therapy Center
dc.contributor.departmentDepartment of Ophthalmology
dc.source.pages563-79


Files in this item

Thumbnail
Name:
hum.2016.040.pdf
Size:
583.9Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright Lolita Petit et al., 2016; Published by Mary Ann Liebert, Inc.
Except where otherwise noted, this item's license is described as Copyright Lolita Petit et al., 2016; Published by Mary Ann Liebert, Inc.